Growth Factor FGF2 Cooperates with Interleukin-17 to Repair Intestinal Epithelial Damage  by Song, Xinyang et al.
ArticleGrowth Factor FGF2 Cooperates with Interleukin-17
to Repair Intestinal Epithelial DamageGraphical AbstractHighlightsd FGF2 and IL-17 signaling are critical for gut homeostasis
during colitis
d Microbiota-driven TGFb1 controls FGF2 production in Treg
cells during colitis
d FGF2 cooperates with IL-17 to promote repair of damaged
intestinal epithelium
d Act1 mediates the cooperation of FGF2 and IL-17 signaling in
gutSong et al., 2015, Immunity 43, 488–501
September 15, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.immuni.2015.06.024Authors
Xinyang Song, Dai Dai, Xiao He, ...,
Xiaoxia Li, Nan Shen, Youcun Qian
Correspondence
nanshensibs@gmail.com (N.S.),
ycqian@sibs.ac.cn (Y.Q.)
In Brief
It remains largely unknown how the
damaged intestinal epithelium is repaired
to rebuild intestinal homeostasis. Song
and colleagues demonstrate that
dysregulated microbiota triggers FGF2
production from Treg cells, and FGF2 in
turn cooperates with Th17-derived IL-17
to promote repair of damaged intestinal
epithelium through adaptor molecule
Act1-mediated signaling cross-talk.Accession NumbersGSE70993
Immunity
ArticleGrowth Factor FGF2 Cooperates with Interleukin-17
to Repair Intestinal Epithelial Damage
Xinyang Song,1,7 Dai Dai,1,7 Xiao He,2 Shu Zhu,1 Yikun Yao,1 Hanchao Gao,1 Jingjing Wang,1 Fangfang Qu,1 Ju Qiu,1
Honglin Wang,3 Xiaoxia Li,4 Nan Shen,1,2,5,6,* and Youcun Qian1,2,*
1The Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of
Sciences/Shanghai Jiao Tong University School of Medicine, Shanghai 200031, China
2Shanghai Institute of Rheumatology, Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200001, China
3Shanghai Institute of Immunology, Institute ofMedical Sciences, Shanghai Jiao TongUniversity School ofMedicine, Shanghai 200025, China
4Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
5State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of
Medicine, Shanghai 200032, China
6Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
7Co-first author
*Correspondence: nanshensibs@gmail.com (N.S.), ycqian@sibs.ac.cn (Y.Q.)
http://dx.doi.org/10.1016/j.immuni.2015.06.024SUMMARY
The intestinal epithelial barrier plays a critical role in
the mucosal immunity. However, it remains largely
unknown how the epithelial barrier is maintained
after damage. Here we show that growth factor
FGF2 synergized with interleukin-17 (IL-17) to induce
genes for repairing of damaged epithelium. FGF2 or
IL-17 deficiency resulted in impaired epithelial prolif-
eration, increased pro-inflammatory microbiota
outgrowth, and consequently worse pathology in a
DSS-induced colitis model. The dysregulated micro-
biota in the model induced transforming growth fac-
tor beta 1 (TGFb1) expression, which in turn induced
FGF2 expression mainly in regulatory T cells. Act1,
an essential adaptor in IL-17 signaling, suppressed
FGF2-induced ERK activation through binding to
adaptor molecule GRB2 to interfere with its associa-
tion with guanine nucleotide exchange factor SOS1.
Act1 preferentially bound to IL-17 receptor complex,
releasing its suppressive effect on FGF2 signaling.
Thus, microbiota-driven FGF2 and IL-17 cooperate
to repair the damaged intestinal epithelium through
Act1-mediated direct signaling cross-talk.
INTRODUCTION
The intestinal microbiota plays a fundamental role in nutrient ab-
sorption as well as in immune system development for the
benefit of human health (Brestoff and Artis, 2013; Clemente
et al., 2012; Hooper et al., 2012; Nicholson et al., 2012). The
mutualistic relationship between the microbiota and host is crit-
ical for maintaining gut homeostasis. The gut epithelium forms a
first line of defense against microbiota and pathogens (Peterson
and Artis, 2014). When the epithelium is damaged and not re-
paired properly, the gut microbiota probably becomes dysregu-
lated (also known as dysbiosis) or mislocated, which activates488 Immunity 43, 488–501, September 15, 2015 ª2015 Elsevier Inc.innate immunity to induce inflammation through pathogen-
recognition receptors such as Toll-like receptors (TLRs), conse-
quently leading to inflammatory diseases including inflammatory
bowel disease (IBD) and colorectal cancer (CRC) (Grivennikov
et al., 2012; Song et al., 2014). However, it is not completely un-
derstood how the damaged epithelium is repaired to rebuild in-
testinal homeostasis to avoid dysbiosis-mediated pathogenesis.
IBD, including ulcerative colitis (UC) and Crohn’s disease (CD),
is a common and debilitating disease with symptoms of fever,
diarrhea, rectal bleeding, cramps, and weight loss (Abraham
and Cho, 2009). The dextran sulfate sodium (DSS)-induced coli-
tis is a commonly utilized mouse model, mimicking the clinical
pathology of UC (Wirtz et al., 2007). IBD is associated withmicro-
biota dysregulation (Manichanh et al., 2012).Whereas the normal
microbiota induces regulatory T cells (Treg) to maintain the tol-
erogenic response in the steady state, dysregulated microbiota
after epithelial damage activates innate immune system to drive
the development of proinflammatory T helper 1 (Th1) and Th17
cell populations for pathogenic immune responses (Belkaid
and Hand, 2014; Smith and Garrett, 2011). Although TGFb1 in-
duces Treg cell differentiation, the existence of proinflammatory
cytokine IL-6 shifts TGFb1 toward Th17 cell differentiation (Bet-
telli et al., 2006; Ivanov et al., 2006; Mangan et al., 2006; Veld-
hoen et al., 2006).
Although Th17 cells are thought to play a proinflammatory role
in the pathogenesis of IBD, IL-17 (also named IL-17A) and IL-22,
the cytokines secreted by Th17 cells, have recently been shown
to have protective roles in experimental colitis (Yang et al., 2008;
Zenewicz et al., 2008). Deficiency of IL-17 signaling results in
exacerbated inflammatory pathogenesis in the DSS-induced co-
litismousemodel (Yang et al., 2008). It is still not very clear how IL-
17 contributes to the protective effect although IL-17 has been
shown to induce genes for tight-junction formation (Kinugasa
et al., 2000). IL-17 associates with its receptor heterodimers (IL-
17RA and IL-17RC) to activate downstream signaling pathways
(Toy et al., 2006;Wright et al., 2008). Act1 is an essential signaling
molecule bridging the IL-17 receptors with the downstream
signaling pathways (Chang et al., 2006; Qian et al., 2007). IL-17
signaling has been shown to be tightly regulated (Qu et al.,
2012; Shi et al., 2011; Song and Qian, 2013; Zhu et al., 2010).
In addition to IL-17, the mitogenic growth factor FGF2 (also
named bFGF) is also increased in IBD (Bousvaros et al., 1997;
Fujino et al., 2003; Tho¨rn et al., 2000). Although administration
of recombinant FGF2 alleviates DSS-induced colitis pathology
(Matsuura et al., 2005), it is not clear how FGF2 functions during
the colitis pathogenesis. FGF2 associateswith its homodimer re-
ceptor FGFR1. FRS2 (the FGF receptor substrate 2) binds to
FGFR1 and recruits the downstream constitutive associated
GRB2-SOS1 complex to activate ERK pathway (Eswarakumar
et al., 2005; Tsang and Dawid, 2004; Turner and Grose, 2010).
FRS2 also binds to SHP2 to form a complex with GRB2
to mediate FGF2-induced ERK signaling (Eswarakumar et al.,
2005). Here we demonstrate that dysregulated microbiota-
driven TGFb1-FGF2 axis cooperates with IL-17 to promote re-
pairing of damaged intestinal epithelial barrier, and Act1 bridges
the direct signaling cross-talk between FGF2 and IL-17 for the
cooperative effect.
RESULTS
FGF2 Cooperates with IL-17 to Promote Repair
of Damaged Intestinal Epithelium
Similar to IL-17 upregulation, FGF2 is reported to be upregulated
in IBD patient samples (Bousvaros et al., 1997; Fujino et al.,
2003; Tho¨rn et al., 2000). To determine whether FGF2 has similar
function as IL-17 in the IBD pathogenesis, we compared the role
of FGF2 and IL-17 in the DSS-induced colitis mouse model. Ge-
netic ablation of FGF2 or IL-17 worsened the colitis phenotype,
including amore severe drop in bodyweight, enhanced intestinal
epithelium damage, shortened colon length, and increased
bleeding score (Figures 1A, 1B, and S1A–S1C), suggesting that
FGF2 has a similar protective role to IL-17 in colitis pathogen-
esis. The similar protective role of FGF2 to IL-17 was also
observed in another mouse colitis model of naive CD4+ T cell
transfer to Rag1-deficient mice (Figures 1C, 1D, and S1D–
S1F). To further understand how FGF2 exerts the protective
function, we analyzed cell proliferation and apoptosis by Ki67
and TUNEL staining, respectively. Deficiency of FGF2 or IL-17
dramatically reduced epithelial cell proliferation without notice-
able impact on cell apoptosis in the DSS-induced colitis model
(Figures 1E–1H), suggesting that FGF2 and IL-17 induce epithe-
lial cell proliferation to promote repair of damaged intestinal
epithelium.
Because FGF2 and IL-17 show similar protective function in
the colitis model, we next tested whether FGF2 could cooperate
with IL-17 to induce genes to promote intestinal epithelium re-
pairing. We performed affymetrix gene chip assay and found
that FGF2 and IL-17 induced some ‘‘unique’’ and overlapping
genes in mouse primary intestinal epithelial cells (IECs) (Fig-
ure S2A). The top list of genes synergistically induced by FGF2
and IL-17 are mainly tissue-repair- and regeneration-related
genes (Figure 2A). However, these synergistically induced genes
are in both unique and overlapping groups, suggesting that
some of the FGF2-induced unique genes might still be induced
by IL-17 although the induction is not easily detected, or vice
versa, that some of the IL-17-induced unique genes might still
be induced by FGF2. We then performed qPCR and confirmed
the synergistic induction of those genes from the gene chip an-
alyses (Figure 2B). The synergistic effect was also observed inImHeLa cells and mouse embryo fibroblast (MEF) cells (Figures
S2B and S2C). Similar to the in vitro results, adenovirus-medi-
ated expression of FGF2 and IL-17 in mice synergistically
induced the wound-healing-related genes in colon in vivo (Fig-
ures 2C and S2D–S2F). FGF2 did not regulate the expression
of the IL-17 receptors both in vitro and in vivo (Figures 2B and
2C). Consistent with the cooperative effect in gene induction,
FGF2 synergized with IL-17 to promote intestinal epithelial cell
proliferation (Figures 2D and 2E). We further found that FGF2
together with IL-17 synergistically induced ERK activation but
not that of p38, JNK, and NF-kB in IECs (Figure 2F), suggesting
that the ERK activation probably contributes to the synergistic
induction of the tissue repair genes. Indeed, the cooperative
gene induction by FGF2 and IL-17 was blocked by a specific
ERK inhibitor in IECs (Figure S3A). Similar synergistic ERK acti-
vation was observed in HeLa cells and MEF cells, and the ERK
inhibitor suppressed FGF2- and IL-17-induced production of
downstream genes in these cells (Figures S3B–S3E). To further
confirm the cooperation of FGF2 and IL-17 in vivo, we deter-
mined whether the protective effect of FGF2 depends on IL-17.
Adenovirus-mediated expression of FGF2 ameliorated DSS-
induced colitis pathology in the wild-type but not Il17a-deficient
mice (Figures 2G–2J), suggesting that FGF2-mediated beneficial
effect requires IL-17 cooperation in vivo. Similarly, adenovirus-
mediated expression of FGF2 but not that of IL-17 improved
DSS-induced colitis in Fgf2-deficent mice (Figures 2K–2N).
These data suggest that FGF2 cooperates with IL-17 in protec-
tion against DSS-induced colitis.
FGF2 and IL-17 Restrain Proinflammatory Microbiota
Outgrowth to Protect against Colitis Pathology
Microbiota dysregulation has been shown to contribute to colitis
pathogenesis and the intestinal epithelial barrier is critical for
maintaining gut microbiota homeostasis (Lupp et al., 2007;
Song et al., 2014; Winter et al., 2013). Our data showed that
both FGF2 and IL-17 were required for gut epithelial cell prolifer-
ation to repair damaged intestinal epithelial barrier and protect
against colitis (Figures 1 and 2). To determine whether micro-
biota contributes to the worsened colitis pathology in the Fgf2-
or Il17a-deficient mice, we used a cocktail of antibiotics to
remove intestinal microbiota and found that the microbiota
depletion blocked DSS-induced colitis pathology in Fgf2- or
Il17a-deficient mice as in wild-type mice (Figures 3A–3D).
Consistent with the reduced epithelial cell proliferation and
enhanced pathology, deficiency of FGF2 or IL-17 increased
proinflammatory gene production but decreased the expression
of proliferation genes in the colitis model (Figure S4A). Similar to
the blockage of the colitis pathology, the microbiota removal
blocked the increased production of the proinflammatory genes
(Figure S4A). We next performed 16S rRNA gene sequencing of
the feces from wild-type, Fgf2- or Il17a-deficient mice during the
colitis model and we found that, after DSS treatment, the fecal
bacterial diversity was reduced (Figures S4B and S4C), accom-
panying with changes in their fecal bacterial composition (Fig-
ure 3E). Further analyses showed that Proteobacteria and Verru-
comicrobia were the upregulated phyla in wild-type mice after
DSS treatment (Figures 3F and S4D), consistent with previous
reports (Arthur et al., 2012; Lupp et al., 2007). However, Proteo-
bacteria was further greatly upregulated while Verrucomicrobiamunity 43, 488–501, September 15, 2015 ª2015 Elsevier Inc. 489
Figure 1. FGF2 or IL-17 Deficiency Leads to Enhanced Pathology in Mouse Colitis Models
(A) Weight loss of WT (n = 6), Il17a/ (n = 5), or Fgf2/ (n = 5) mice during the progress of DSS-induced colitis.
(B) H&E histology of the representative colons from the mice on day 10 of the colitis model as in (A) (2003 magnification).
(C) Weight loss of Rag1/ mice transferred with CD45RBhi T cells purified from WT (n = 8), Il17a/ (n = 9), or Fgf2/ (n = 9) mice during the progress of T cell
transfer model of colitis.
(D) H&E histology of the representative colons from the mice on day 63 of the colitis model as in (C) (1003 magnification).
(E and F) Ki67 staining (E) of the representative colons from the mice on day 0 and day 10 of the colitis model as in (A) (4003 magnification). The number of
proliferating cells per crypt (F) was determined as in (E) (n = 5/group, 5 crypts were counted per mice).
(G and H) TUNEL staining (G) of the representative colons from the mice on day 5 or day 10 of the colitis model as in (A) (4003 magnification). The number of
apoptotic cells per field (H) was counted as in (G) (n = 7/group).
Data are representative of two (C and D) or three (A, B, E–H) independent experiments (mean and SEM in A, C, F, and H). *p < 0.05, **p < 0.01, ***p < 0.001 by
Student’s t test. See also Figure S1.
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Figure 2. FGF2 Cooperates with IL-17 to Promote Intestinal Epithelium Wound Healing
(A) Heatmap of the top list of the genes synergistically induced by IL-17 and FGF2 from gene chip analyses in mouse primary IECs, left untreated (UN) or
stimulated for 6 hr with IL-17 (50 ng/ml), FGF2 (5 ng/ml), or both.
(B) Quantitative mRNA expression of the indicated genes in IECs treated as in (A).
(C) Quantitative mRNA expression of the indicated genes in the colons of C57BL/6 mice treated with empty virus (Adv-EV), or adenovirus expressing IL-17
(Adv-IL-17), FGF2 (Adv-FGF2), or IL-17 plus FGF2 (n = 4/group) for 4 days.
(D and E) Ki67 staining (D) of the representative colons from the mice treated as in (C) (4003 magnification). The number of proliferating cells per crypt (E) was
determined as in (D) (n = 5/group, 5 crypts were counted per mice).
(legend continued on next page)
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was not increased in the feces of both Fgf2- and Il17a-deficient
mice (Figures 3F and S4D). Enterobacteriacease was the only
observed upregulated family of Proteobacteria phylum (Fig-
ure 3G). While both Enterobacter and Escherichia, the genera
of Enterobacteriacease, were upregulated inwild-typemice after
DSS treatment, Escherichia but not Enterobacter was further
increased in the feces of both Fgf2- and Il17a-deficientmice (Fig-
ure S4E). We then confirmed the upregulation of Proteobacteria,
Enterobacteriacease and Escherichia coli (E. coli) by qPCR in the
feces or colon mucosal surface of both Fgf2- and Il17a-deficient
mice (Figures 3H and 3I). To further know if the increased E. coli
contributes to the enhanced pathology, we took use of germ-free
(GF) mice and found that E. coli in deed promoted DSS-induced
colitis (Figures 3J, 3K, and S4F). Thus, our data suggest that defi-
ciency of IL-17 or FGF2 leads to reduced tissue repair, dysbiosis
and consequently worsened colitis pathology.
Dysregulated Microbiota Induces FGF2 Expression
in Treg Cells through TGFb1
Although it is reported that FGF2 is upregulated in IBD patients
(Bousvaros et al., 1997; Tho¨rn et al., 2000), it is not known how
FGF2 is induced in the pathogenesis of IBD. As predicted, we
observed that FGF2 was induced in the colons of specific
pathogen free (SPF) mice after DSS treatment, similar to IL-17
induction (Figures 4A and S5A). FGF2 was not induced in the co-
lons of GFmice (Figure 4A), indicating that microbiota is required
for FGF2 induction during colitis. While IL-17 induction was de-
tected at later time points in GF mice by DSS treatment, the in-
duction was minimal compared to that in SPF mice (Figure S5A).
Similarly, antibiotics mediated removal of microbiota blocked
FGF2 and IL-17 induction (Figures 4B and S5B). These data sug-
gest that both IL-17 and FGF2 are mainly induced by microbiota
in the colitis model. We further found that FGF2 was induced in
lamina propria lymphocytes (LPL), similar to IL-17 induction (Fig-
ures 4B and S5B). As the mucosal T cells in lamina propria are
master cells for keeping intestinal barrier homeostasis (Smith
and Garrett, 2011), we next determined if T cells contribute to
FGF2 induction. By utilizing Rag2-deficient mice, we found that
RAG2 deficiency significantly impaired FGF2 induction, while
CD4+ T cell transfer restored the impaired induction (Figure 4C),
suggesting that CD4+ T cells are important for FGF2 induction
during colitis. Similar observation was found for IL-17 induction
as predicted (Figure S5C). Consistent with CD4+ T cell mediated
production of FGF2 and IL-17, the T cell transfer partially
restored intestinal epithelial proliferation and consequently
DSS-induced colitis pathology in Rag2-deficient mice (Figures
4D–4G). The partial restoration in this transfer system is likely(F) Immunoblot analysis of the indicated phosphorylated- (p-) proteins and Acti
(50 ng/ml), FGF2 (5 ng/ml), or FGF2 plus IL-17.
(G) Weight loss of WT or Il17a/mice treated with empty virus (Adv-EV) or adeno
(n = 6/group).
(H and I) H&E histology (2003 magnification) of the representative colon section
(J) Bleeding scores and stool scores on day 7 of the colitis model as in (G).
(K) Weight loss of Fgf2/mice treated with empty virus (Adv-EV) (n = 4), adenov
progress of DSS-induced colitis.
(L and M) H&E histology (2003 magnification) of the representative colon section
(N) Bleeding scores and stool scores on day 7 of the colitis model as in (K).
Data are representative of three (B–F) or two (A and G–N) independent experiment
by Student’s t test. See also Figures S2 and S3.
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role in the mucosal system (Kirkland et al., 2012). Fgf2-deficient
CD4+ T cells failed to restore the epithelial proliferation and colitis
pathology (Figures 4D–4G), suggesting that CD4+ T cell medi-
ated FGF2 induction is critical for the epithelium repair and colitis
amelioration.
To understand how FGF2 is induced in CD4+ T cells, we first
analyzed Th1, Th2, Th17 andTreg cell populations in colonic lam-
ina propria after DSS treatment. We found that both Th2 cell per-
centages and numbers were very low and not increased after
DSS treatment while the other populations were increased after
DSS treatment (Figures S5D and S5E), indicating the Th2 cell
population is likely not important for FGF2 expression in the co-
litis model. We then found that FGF2 was strongly induced in
both in vitro differentiated Th17 and Treg cells but not in Th1 cells
(Figure 4H). As TGFb1 was utilized in both in vitro differentiation
conditions for Th17 and Treg cells, we then utilized the conditions
without TGFb (IL-1b and IL-6 and IL-23) for Th17 cell differentia-
tion and found that IL-17 but not FGF2was induced and the cyto-
kine combination did not increase TGFb1-induced FGF2 expres-
sion (Figure S5F). These results indicate that TGFb1 is critical for
FGF2 induction and that Treg but not Th17 cells are likely impor-
tant for FGF2 production.We also observed that both TGFb1 and
FGF2 were induced at similar kinetics after DSS challenge (Fig-
ure 4I), and thatmicrobiotawasalso required for TGFb1 induction
(Figures 4I–4K). We further found that TGFb1 was mainly pro-
duced by LPLs and weakly produced by IECs during colitis (Fig-
ure 4K) and that CD4+ T cell restoration in Rag2-deficient mice
recovered its induction in colon (Figure 4L), suggesting that
TGFb1 may be important for FGF2 induction in the colitis model.
We also found that TGFb1 only weakly induced FGF2 expression
in IECs and that microbiota related PAMPs did not (Figure S5G),
suggesting that TGFb1 specifically induces FGF2 expression
and T cells are probably the main FGF2 producing cells. To
confirm the importance of TGFb1 in FGF2 induction in vivo, we
utilized TGFb blocking antibody and found that TGFb blockage
reduced FGF2 expression in the colitis model (Figure 4M). The
TGFb blockage reduced Treg but not Th17 cell percentages (Fig-
ures S5H–S5J), indicating that Treg cells instead of Th17 cells are
mainly responsible for the FGF2 induction in the colitis model. In
contrast, antibody mediated blockage of IL-23 signaling sup-
pressed Th17 but not Treg cell population (Figures S5H–S5J)
and did not reduce FGF2 induction (Figure 4N). Similarly, Th17
but not Treg cell population was reduced in Il6-deficient colons
after DSS treatment (Figures S5K and S5L), and FGF2 induction
was not affected by IL-6 deficiency (Figure 4O). Consistent with
the protective roles of Treg and Th17 cells, antibody blockagen in lysates of IECs left untreated (0) or treated for 10 and 20 min with IL-17
virus expressing FGF2 (Adv-FGF2) during the progress of DSS-induced colitis
s (H) or colon length (I) on day 10 of the colitis model as in (G).
irus expressing IL-17 (Adv-IL-17) (n = 5), or FGF2 (Adv-FGF2) (n = 5) during the
s (L) and colon length (M) on day 10 of the colitis model as in (K).
s (mean and SEM in B, C, E, G, I–K, M, and N). *p < 0.05, **p < 0.01, ***p < 0.001
Figure 3. Dysregulted Microbiota Is Critical for the Enhanced Pathology out of Genetic Ablation of FGF2 or IL-17
(A) Weight loss of WT, Il17a/, or Fgf2/ mice treated with or without a cocktail of antibiotics during the progress of DSS-induced colitis (n = 4 or 5/group).
(B and C) H&E histology (2003magnification) of the representative mouse colons (B) or colon length (C) on day 10 of the colitis model as in (A) (n = 4 or 5/group).
(D) Bleeding scores and stool scores on day 7 of the colitis model as in (A) (n = 4 or 5/group).
(E) Principal coordinates analysis (PCoA) of microbiome in fecal specimens fromWT, Il17a/, or Fgf2/mice on day 0 or day 8 of the colitis model (n = 6/group)
by 16S rRNA gene sequencing.
(F) Average relative abundance of bacterial phyla of microbiota in fecal specimens by taxon-based analyses as in (E) (n = 6/group).
(G) Heatmap depicting of relative abundance of family level microbiota in the feces as in (E) (n = 3/group).
(legend continued on next page)
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with anti-TGFb and anti-IL-23R as well as IL-6 deficiency all
enhanced DSS-induced colitis (Figures S5M–S5P). We further
utilized Foxp3-GFP reporter mice, in which GFP is expressed un-
der control of the foxp3 promoter, and found that FGF2 was
mainly expressed by CD4+Foxp3+ T cells (Treg) while IL-17 was
mainly expressed by CD4+Foxp3 T cells (Figure 4P). Consistent
with the major FGF2 induction in Treg cells, Foxp3+ Treg cells
were the major LPL T cell population and further increased by
DSS treatment (Figures S5D and S5E). To firmly exclude the
involvement of Th17 cells in FGF2 expression, weutilized transfer
of CD4+ T cells deficient in Rorc, a key transcription factor for
Th17 development, and found that Rorc-deficient T cells were
critical for IL-17 induction but not important for FGF2 induction
in the colitis model (Figures 4Q and S5Q). Together, our data
strongly suggest that Treg cells are the major T cell population
for FGF2 induction in the DSS-induced colitis model.
Act1 Is a Negative Regulator of FGF2-Induced ERK
Signaling
We observed that FGF2 and IL-17 synergically induced ERK
activation (Figure 2F), suggesting that there may be direct
signaling cross-talk for the ERK pathway. Act1 is an essential
molecule in IL-17 signaling. We found that Act1 also interacted
with the signaling molecules upstream of FGF2-induced ERK
pathway including FGF2 receptor (FGFR1), FRS2a, SHP2 and
GRB2 except for SOS1 in the overexpression system (Figures
S6A–S6E), indicating that Act1 might be directly involved in
FGF2-induced ERK signaling. Indeed, we found that FGF2-
induced ERK activation rather than other MAPK pathways
including P38 and JNK was specifically enhanced in the Act1-
silencing DLD1 cells (Figure 5A) or HEK293 cells (Figure S6F).
We observed that knockdown of IL-17RA or IL-17RC did not
affect FGF2 induced ERK activation (Figures S6G and S6H).
Similarly, FGF2 induced ERK activation was not affected in
Il17rc-deficient primary IECs (Figures S6I and S6J), suggesting
the specific effect of Act1 in FGF2 signaling. Consistent with
the signaling results, Act1 gene knockdown increased FGF2-
induced downstream genes production (Figure 5B). Similarly,
Act1 restoration into Act1-deficient MEF cells specifically sup-
pressed FGF2-induced ERK activation and consequently in-
hibited FGF2-induced genes production (Figures 5C and 5D).
These data indicate that Act1 specifically suppresses FGF2-
induced ERK signaling to inhibit induction of downstream genes.
Wenextwent to determinewhether Act1 is recruited into FGFR
complex after FGF2 ligation. Indeed, we observed that endoge-
nous Act1 bound to transiently overexpressed FGFR1 or FRS2a
uponFGF2stimulation (FigureS6K). Similarly, co-immunoprecip-
itation experiments showed that endogenous Act1 associated
with endogenous GRB2 or SHP2 in a FGF2-signal dependent
manner in HEK293 cells (Figures S6L and S6M). This signal
dependent interaction of Act1 with GRB2 was also observed by
co-immunoprecipitation in HeLa, DLD1 and MEF cells (Figures(H and I) Quantitative PCR of 16S rRNA genes of Proteobacteria phylum, Enterob
mucosal surface (I) of the indicated mice on day 0 or day 10 (n = 3–4/group) of th
(J) Weight loss of germ-free (GF) mice treated for the indicated time points with
(K) H&E histology of the representative colons from GF mice left untreated (UN)
Data are representative of two (A–G, J, and K) or three (H and I) independent exper
Student’s t test. See also Figure S4.
494 Immunity 43, 488–501, September 15, 2015 ª2015 Elsevier Inc.5E–5H). Consistent with the signaling in HT-29 cells (Figure S6H),
IL-17 receptor silencing did not affect the signal dependent inter-
action of Act1 with GRB2 or SHP2 (Figure S6N). These results
suggest that Act1 is specifically recruited to FGF2-receptor com-
plex to suppress its downstream ERK signaling.
Act1 directly associates with GRB2 to dissociate the
GRB2-SOS1 complex
TounderstandhowAct1 interactswith thoseFGF2-signalingmol-
ecules, we analyzed Act1 protein sequence by ClustalW2 align-
ment and found that Act1 contains a conserved proline rich
domain (Figure S7A). As GRB2 is reported to directly associate
with the proline rich domains of its partners such as SOS1 (Char-
din et al., 1993; Li et al., 1993; Olivier et al., 1993), we tested
whether Act1 directly binds to GRB2 by GST-pull down assay.
Indeed, we found that Act1 directly associated with GRB2 (Fig-
ure 6A). Consistently, the Act1 mutant with deletion of the proline
rich domain lost its binding ability to GRB2 (Figures S7B–S7E).
Further domain mapping analysis showed that amino acid 330-
384 region in this domain was required for its binding to GRB2
(Figures 6B, 6C, and S7B-S7E). The GRB2 protein consists of
two SH3 domains in the N- and C-termini and one SH2 domain
in the middle (Figure S7F). Deletion of either of the SH3 domains
blocked the association of GRB2with Act1while the SH2 domain
mutation did not (Figure S7G), indicating that GRB2 may asso-
ciatewith Act1 through theSH3domains. Indeed, the pointmuta-
tions of the critical residue tryptophan (W) to lysine (K) in the SH3
domains reduced the association of GRB2 with Act1 (Figures 6D
and 6E). As Act1 directly associated with GRB2, we next deter-
mined whether Act1 interacts with other FGF2-signaling mole-
cules through GRB2. We found that GRB2 gene silencing
decreased the association of Act1 with FGFR1 or SHP2 while
GRB2 overexpression promoted the association (Figures 6F
and 6G), indicating that Act1 is recruited to FGFR1 and SHP2
through GRB2. Considering that Act1 and SOS1 bind to the
samedomainsofGRB2,wehypothesized thatAct1maycompete
with SOS1 for GRB2 binding. Indeed, we found that overexpres-
sion of SOS1 inhibited the association of Act1 with GRB2 while
Act1 gene knock-down increased the binding of SOS1 with
GRB2 (Figures 6H and 6I). Furthermore, the association of
SOS1 with GRB2 was suppressed by wild-type Act1, but not its
proline rich domain deletionmutant, in a dose dependentmanner
(Figures 6J–6L). Consistently, the Act1 deletionmutant hadmuch
less suppressive effect than wild-type Act1 on FGF2-induced
ERK activation (Figure 6M). Together, these results suggest that
Act1 specifically suppresses FGF2-induced ERK signaling by
directly interfering with the GRB2-SOS1 complex formation.
Act1 Is Preferentially Recruited to IL-17 Receptors to
Release Its Suppressive Effect on FGF2 Signaling
Considering that Act1 is required for IL-17 signaling while Act1
suppressed FGF2- signaling, we hypothesized that IL-17acteriaceae family, and E. coli species in the luminal specimens (H) or at colon
e colitis model.
DSS (n = 5), E. coli alone (n = 4), or with DSS plus E.coli (n = 5).
or treated as in (J) on day 10 of the colitis model (2003 magnification).
iments (mean and SEM in A, C, D, and H–J). *p < 0.05, **p < 0.01, ***p < 0.001 by
Figure 4. Microbiota-Driven TGFb1 Controls FGF2 Production from Regulatory T Cells during Colitis
(A) Quantitative mRNA expression of FGF2 in the colons of specific-pathogen-free (SPF) mice or GF mice at the indicated time points of the colitis model
(n = 4/group).
(B) Quantitative mRNA expression of FGF2 in the LPLs or IECs from the C57BL/6 mice treated with or without the antibiotics (Abx), and then left unstimulated or
stimulated for the colitis model (n = 4/group).
(C) Quantitative mRNA expression of FGF2 in the colons of Rag2+/, Rag2/, or Rag2/mice transferred with wild-type CD4+ T cells on day 0 or day 6 of the
colitis model (n = 4/group).
(D and E) Ki67 staining (D) of the representative colons fromRag2+/,Rag2/, andRag2/mice transferredwith wild-type or Fgf2/CD4+ T cells on day 6 of the
colitis model (4003 magnification). The number of proliferating cells per crypt (E) was determined as in (D) (n = 5/group, 5 crypts were counted per mouse).
(legend continued on next page)
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receptors may have stronger binding affinity than GRB2 to Act1
for synergistic ERK activation by IL-17 plus FGF2. We have pre-
viously reported that overexpressed IL-17RA interacted with
Act1 while endogenous IL-17RA associated with Act1 only after
IL-17 stimulation (Qian et al., 2007). Consistent with our hypoth-
esis, we found that overexpression of either IL-17RA or IL-17RC
suppressed the association of GRB2 with Act1 in a dose depen-
dent manner (Figure 7A). Furthermore, overexpression of
IL-17RA suppressed the binding of GRB2 with Act1 in a FGF2-
signal dependent manner (Figure 7B). To prove the preferential
binding hypothesis for Act1-mediated cooperative signaling of
FGF2 and IL-17, we determined whether FGF2-induced associ-
ation of Act1 with GRB2 is affected by IL-17 co-stimulation.
Indeed, we found that IL-17 plus FGF2 suppressed FGF2-
induced association of Act1 with GRB2 as well as FGFR1 and
SHP2 in HeLa cells (Figure 7C). In contrast, FGF2 together with
IL-17 co-stimulation exhibited little suppressive effect on
IL-17-induced association of Act1 with IL-17RA (Figure 7D).
We also found that IL-17 suppressed FGF2 induced association
of Act1with GRB2 inmouse primary IECs (Figure 7E). These data
suggest that, when IL-17 and FGF2 co-exist in a condition such
as IBD pathogenesis, Act1 is preferentially recruited to IL-17 re-
ceptors, removing the suppressive effect of Act1 on FGF2-
induced ERK signaling for synergistically induction of tissue
repair related genes.
DISCUSSION
The intestinal epithelium is a critical barrier for protection against
potential harmful microbiota (pathoboint) or pathogens (Peter-
son and Artis, 2014). The epithelial barrier is damaged during in-
flammatory colon diseases such as colitis and its associated co-
lon cancer (Grivennikov et al., 2012; Song et al., 2014). It is not
clear how the damaged epithelium is adequately repaired to
reinstitute the gut homeostasis. Here we demonstrate that dys-
regulated microbiota after the epithelial barrier damage upregu-
lates TGFb1, TGFb1 in turn induces FGF2 expression mainly
through Treg cells, and then FGF2 synergies with IL-17 to induce
genes to repair the damaged epithelium.
We and others previously showed that facultative anaerobic
bacteria Enterobacteriaceae, especially E. coli species, the
proinflammatory bacteria, dramatically outgrew after DSS-
induced epithelial damage and consequently resulted in inflam-
matory pathology (Lupp et al., 2007; Song et al., 2014; Winter
et al., 2013). Here we found that deficiency of FGF2 or IL-17(F and G) Weight loss and survival (F) or H&E histology (2003magnification) of the
DSS-induced colitis (n = 6/group).
(H) Quantitative mRNA expression of FGF2 in the T cells differentiated under Th0
(I) Quantitative mRNA expression of FGF2 and TGFb1 in the colons from the mic
(J) Quantitative mRNA expression of TGFb1 in the colons of SPF or GF mice at t
(K) Quantitative mRNA expression of TGFb1 in the LPLs or IECs from the mice tr
(L) Quantitative mRNA expression of TGFb1 in the colons as in (C) (n = 4/group).
(M–O) Quantitative mRNA expression of FGF2 in the colons of WTmice (UN) or WT
mice (O) on day 0, day 8 (O), or day 10 (M and N) of the colitis model (n = 4/grou
(P) Quantitative mRNA expression of FGF2 and IL-17 in sorted Foxp3, or Foxp3+
(Q) Quantitative mRNA expression of FGF2 in the colons of Rag2+/, Rag2/, or
the colitis model (n = 4/group).
Data are representative of two (A, C–G, J, L–O, and Q) or three (B, H, I, K, and P) in
0.01, ***p < 0.001 by Student’s t test. See also Figure S5.
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through 16S rRNA gene sequencing, consistent with the
severer colitis pathology and enhanced inflammatory gene pro-
duction in colon, while the antibiotics mediated microbiota
removal blocked the inflammatory pathology. We further
demonstrated that the outgrown E. coli promoted DSS-induced
colitis. Thus, our data indicate that FGF2 and IL-17 control the
microbiota outgrowth to suppress the colitis pathogenesis.
Deficiency of FGF2 or IL-17 led to similar colitis pathology,
impaired epithelial proliferation, and outgrowth of the proin-
flammatory microbiota. Importantly, the improved colitis effect
by FGF2 required IL-17, and vice versa IL-17 mediated protec-
tion required FGF2. Through gene chip analyses, we demon-
strated that FGF2 and IL-17 synergized to induce many tissue
repair related genes. We also provided evidence that FGF2
cooperated with IL-17 to promote epithelial cell proliferation.
Together, our data support that FGF2 cooperates with IL-17
to promote epithelium repairing to protect against damage
induced colitis.
FGF2 is upregulated in IBD patients (Bousvaros et al., 1997;
Tho¨rn et al., 2000). However, it is not known how FGF2 expres-
sion is regulated. We found that dysregulated microbiota
was required for FGF2 upregulation as demonstrated by both
GF mice and antibiotics mediated removal of microbiota. We
further demonstrated that CD4+ T cells were important sources
for FGF2 in the colitis model by transfer of wild-type or Fgf2-defi-
cient CD4+ T cells into Rag2-deficient mice. Importantly, we
found that TGFb1 specifically induced FGF2 expression in Treg
in vitro, and the TGFb1 mediated FGF2 induction was further
confirmed in vivo by administration of TGFb blocking antibody.
By utilizing the Foxp3-GFP reporter mice, we found that CD4+
Foxp3+ Treg cells were the main population for FGF2 production
while CD4+Foxp3 T cells were the main population for IL-17
production. We also provided strong evidence that Th17 cells
were not important for FGF2 production in the DSS-induced
colitis model by utilizing IL-23R blocking antibody, Il6-deficient
mice or Rorc-deficient CD4+ T cell transfer. We further provided
evidence that Th1 and Th2 cells were not likely important for
FGF2 induction in the colitis model. Putting together, our data
strongly suggest that Treg cells are the major T cell population
for FGF2 induction. However, we could not exclude the possibil-
ity of the contribution of other cell types in FGF2 induction in vivo
as we found that TGFb1 weakly induced FGF2 expression in
IECs and IECs produced minor amount of FGF2 during DSS-
induced colitis. By showing that Treg and Th17 cells are requiredrepresentative colons (G) on day 6 of the indicated mice during the progress of
, Th1, Th17, and Treg cell conditions.
e treated as in (B) (n = 4/group).
he indicated time points of the colitis model (n = 4/group).
eated as in (B) (n = 4/group).
mice treated with control IgG, anti-TGFb (M), anti-IL-23R (N), or WT and Il6/
p).
CD4+ T cells from Foxp3-GFP reporter mice on day 8 of the colitis model.
Rag2/mice transferred with WT or Rorc/ CD4+ T cells on day 0 or day 6 of
dependent experiments (mean and SEM in A–C, E, F, and H–Q). *p < 0.05, **p <
Figure 5. Act1 Is Recruited to FGFR Signaling Complex and Suppresses FGF2-Induced ERK Activation
(A) Immunoblot analysis with antibodies against the indicated phosphorylated (p-), Act1 or Actin proteins in lysates of DLD1 cells infected with control lentivirus or
the lentivirus for Act1-specific siRNA (Si-Act1) and then left untreated (0) or treated for 2.5–60 min with FGF2 (50 ng/ml).
(B) Quantitative mRNA expression of the indicated genes in DLD1 cells infected as in (A), and then left untreated (0) or treated for 1 hr with FGF2 (50 ng/ml).
(C) Immunoblot analysis with antibodies against the indicated phosphorylated (p-), Flag-tagged, or Actin proteins in lysates of Act1-deficient MEFs infected with
empty virus (MSCV) or the virus encoding Flag-tagged WT Act1 (M2-Act1) and then left untreated (0) or treated for 2.5–60 min with FGF2 (50 ng/ml).
(D) Quantitative mRNA expression of the indicated genes in Act1-deficient MEFs infected as in (C), and then left untreated (0) or treated for 1 hr with FGF2
(50 ng/ml).
(E–H) Co-immunoprecipitation of cell lysates from HeLa cells (E and F), DLD1 cells (G), and MEF cells (H). Cells were left untreated (0) or treated for the indicated
time points with FGF2 (50 ng/ml). Whole cell lysates were immunoprecipitated with anti-Act1 (E, G, and H) or anti-GRB2 (F) and immunoblotted with the indicated
antibodies. NS, nonspecific.
Data are representative of three (A–F) or two (G and H) independent experiments (mean and SEM in B and D). *p < 0.05, **p < 0.01 by Student’s t test. See also
Figure S6.for the induction of FGF2 and IL-17 respectively in the colitis
model and that FGF2 cooperates with IL-17 to repair the
damaged epithelium, our data suggest that both the immuno-
suppressive Treg cells and the proinflammatory Th17 cells
contribute to the gut epithelial tissue regeneration for the reinsti-
tution of intestinal homeostasis during colitis.ImFGF2 signaling recruits FRS2a, GRB2, and SHP2 to FGFR-
complex (Gotoh, 2008). GRB2 constitutively associates with
SOS1 for downstream Ras-ERK activation. The association is
through the SH3 domains of GRB2 and the proline rich domain
of SOS1. We predicted a proline rich domain in Act1 protein
through a bioinformatics approach. Importantly, we found thatmunity 43, 488–501, September 15, 2015 ª2015 Elsevier Inc. 497
Figure 6. Act1 Directly Associates with GRB2 and Competes with SOS1 for GRB2 Binding
(A) GST-pull down assay using in vitro translated Flag-tagged Act1 (M2-Act1) combined with bacterial expressed and purified GST-EV or GST-GRB2.
(B) Schematic representation of full-length Act1 and its proline-rich domain deletion mutant.
(C) Co-immunoprecipitation of cell lysates from HEK293 cells expressing Flag-tagged Act1 (M2-Act1) or its deletion mutant M2-Act1-d330-384. Whole cell
lysates were immunoprecipitated (IP) and immunoblotted (IB) with the indicated antibodies.
(D) Schematic representation of full-length GRB2 and its deletion or point mutants.
(E–L) Co-immunoprecipitation of cell lysates from HEK293 cells expressing Flag (M2)-tagged Act1 (M2-Act1) and the SH2 or SH3 domian point mutants of
hemagglutinin (HA)-tagged GRB2 (E), HEK293 cells expressing M2-FGFR1 and HA-SHP2 in the presence or absence of HA-GRB2 (F), HEK293 cells expressing
HA-FGFR1 andHA-SHP2 that were infectedwith control virus or virus for GRB2-specific siRNA (G), HEK293 cells expressing HA-Act1 in the presence or absence
of HA-SOS1 (H), HEK293 cells expressing HA-SOS1 that were infected with control virus or the virus for Act1-specific siRNA (I), HEK293 cells expressing HA-
GRB2 that were transfected with increasing amounts of plasmids for M2-Act1 (J), and HEK293 cells expressing HA-SOS1 that were transfected with increasing
amounts of plasmids for HA-Act1 (K) or M2-Act1-dPro mutant (L). Whole cell lysates were immunoprecipitated and immunoblotted with the indicated antibodies.
(M) HEK293 cells with stably Act1 siRNA silencing were restored with empty vectors (EV), Flag-tagged wild-type Act1 (Act-WT), or Flag-tagged Act1 proline-rich
domain deletion mutant (Act-dPro). Cells were left untreated (0) or treated for the indicated time points with FGF2 (50 ng/ml). Whole cell lysates were im-
munoblotted with the indicated antibodies. Data are representative of three independent experiments. See also Figure S7.
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Figure 7. Act1 Preferentially Binds to IL-17
Receptor to Release Its Suppressive Effect
on FGFR1 Signaling
(A) HEK293 cells expressing M2-FGFR1 were
transfected with increasing amounts of plasmids
for HA-IL-17RA or IL-17RC.
(B) HEK293 cells expressing M2-FGFR1 were
transfected with empty vector (EV) or expression
vector for HA-IL-17RA. Cells were left untreated
(0) or treated for 10 and 20 min with FGF2
(50 ng/ml).
(C) HeLa cells expressing M2-FGFR1 were left
untreated (0) or treated for 10 and 20 min with
FGF2 (50 ng/ml) in the absence or presence of IL-
17 (50 ng/ml).
(D) HeLa cells expressing HA-IL-17RA were left
untreated (0) or treated for 10 and 20 min with IL-
17 (50 ng/ml) in the absence or presence of FGF2
(50 ng/ml).
(E) Mouse IECs were left untreated (0) or treated
as in (C). Whole cell lysates were immunoprecip-
itated and immunoblotted with the indicated an-
tibodies.
Data are representative of three (A and B) or two
(C–E) independent experiments.Act1 directly associated with GRB2, and the proline rich domain
of Act1 was essential for its binding with either of the SH3 do-
mains of GRB2. We further found that while Act1 interacted
with FGFR1, FRS2a, SHP2 and GRB2 in a FGF2-signal depen-
dent manner, the association of Act1 with the FGF2 signaling
components was severely blocked after GRB2 gene knock-
down, indicating that Act1 is recruited to the FGFR1 complex
through its direct association with GRB2. Instead of activating
the signaling, we found that Act1 suppressed FGF2-induced
ERK activation by competing with SOS1 for GRB2 binding.
Furthermore, deletion of the proline rich domain blocked
Act1’s ability to compete with SOS1 for GRB2 binding, and
consequently the suppressive effect of Act1 on FGF2 signaling.
Thus, our study identifies Act1 as a new negative regulator of
FGF2-induced ERK signaling through its direct association
with GRB2.
While we found that Act1 suppressed FGF2 signaling, Act1 is
essential for IL-17 signaling. However, we found that IL-17 syn-
ergized with FGF2 to induce ERK activation. This paradox is
solved by the hypothesis supported by our data that Act1 is pref-
erentially recruited to IL-17 receptor complex, thus releasing theImmunity 43, 488–501, Sesuppressive effect of Act1 on FGF2
signaling. We found that both IL-17RA
and IL-17RC overexpression sup-
pressed the association of Act1 with
GRB2. We further found that FGF2-
induced association of Act1 with GRB2
was suppressed by IL-17 co-stimulation,
indicating that Act1 preferentially associ-
ates with IL-17 receptors during the co-
stimulation. As SEF domains are shown
to mediate the association of Act1 with
these receptors (Qian et al., 2007), it is
likely that the SEF domains are respon-sible for the preferential association. IL-17 has also been re-
ported to activate an Act1-dependant and TRAF6-independent
signaling pathway to stabilize themRNAs such as the chemokine
KC induced by TNFa (Bulek et al., 2011; Hartupee et al., 2009;
Sun et al., 2011), thus amplifying TNFa-mediated inflammatory
response. Here we demonstrate that IL-17 synergizes with
FGF2 in downstream gene induction through a different mecha-
nism, i.e., the direct signaling cross-talk. The receptors for FGF2
and IL-17 are ubiquitously expressed in different cell types
(Hughes, 1997; Ishigame et al., 2009). We found that IL-17 had
much stronger responses in fibroblasts and epithelial cells than
in hematopoietic cells (data not shown), suggesting that IL-17
cooperates with FGF2 to mainly target epithelial cells and stro-
mal cells in colitis for tissue repair and regeneration.
In summary, we demonstrate that dysregulated microbiota in-
duces TGFb1 expression, TGFb1 in turn induces FGF2 expres-
sion mainly in Treg cells, and then FGF2 cooperates with
Th17-cell-derived IL-17 to synergically induce genes to promote
epithelial cell proliferation for repair of the colitis-associated in-
testinal epithelium damage. We identify Act1 as a new negative
regulator of FGF2-induced ERK signaling by competing withptember 15, 2015 ª2015 Elsevier Inc. 499
SOS1 for GRB2 binding. We discover a new ‘‘relief of suppres-
sion’’ mechanism for the Act1-mediated direct signaling cooper-
ation of IL-17 with FGF2. Our study indicates that Treg and Th17
cells cooperate in promoting repair of damaged intestinal epithe-
lium through expressing FGF2 and IL-17, respectively, during
colitis.
EXPERIMENTAL PROCEDURES
Mice
Fgf2/, Il17a/, Rag1/, Rag2/, Il6/, and their representative wild-type
or heterozygous control mice weremaintained in specific-pathogen-free (SPF)
facility without cohousing. Foxp3GFP+ transgenic mice and Rorc(gt)-EGFP
mutant mice were also maintained in SPF facility. Germ-free mice on
C57BL/6 background were maintained in germ-free facility. All animal experi-
ments were performed in compliance with the guide for the care and use of
laboratory animals and were approved by the institutional biomedical research
ethics committee of the Shanghai Institutes for Biological Sciences, Chinese
Academy of Sciences.
Induction of Colitis
6- to 8-week-old indicated mice were given with 2.5% DSS (MP Biomedicals)
in drinking water for 5 days, then followed with regular water for another
5 days. For DSS-induced colitis in Rag2/ mice, mice were intravenously in-
jected with 43 106 CD4+ T cells purified by magnetic cell sorting from spleens
of the indicatedmice and then treatedwith 2.5%DSS as described on the sec-
ond day of injection. Mice were sacrificed for tissue analyses on days 6, 8, or
10 of the different experimental settings. For induction of colitis in germ-free
(GF) mice, 6- to 8-week-old indicated mice on C57BL/6 background were
treated with 2.0% DSS for 5 days, during which at day 2 the mice were given
1010 CFU of E. coli that were isolated from EMB plate by gavage. The mice
were weighed during the colitis model and sacrificed on the indicated time
points of the colitis model, and colon tissues were obtained for histopatholog-
ical and RT-PCR analyses. The SPFC57BL/6 background wild-typemicewere
also treated with 2.0% DSS for comparing in this assay. Scoring for occult
blood and stool consistency was done as previously described (Song et al.,
2014).
T Cell Adoptive Transfer Model of Colitis
The indicated naive T cells (CD4+CD25CD45RBhi) were sorted by flow cytom-
etry (ARIA III; BD Biosciences) from the spleens of 6- to 8-week-old WT,
Il17a/, or Fgf2/mice. 43 105 cells in 200 ml sterile PBS were then intraper-
itoneally injected into Rag1/ recipient mice. The mice were weighed
throughout the colitis model to assess their weight loss. Representative colon
tissues were harvested for histopathological and RT-PCR analyses.
Histology
Colon tissues for histological analyses were dissected from the DSS-chal-
lenged mice, adenovirus-treated mice, or control mice and immediately fixed
with 4% paraformaldehyde. Paraffin-embedded sections of the indicated co-
lons were subjected to H&E or IHC staining and then examined by light
microscopy.
RNA Isolation and Real-Time Quantitative PCR
Total RNA was extracted from the indicated cells or mouse colon tissues with
TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. RNA
samples were reverse-transcribed into cDNA with a PrimeScript RT Reagent
kit (TaKaRa). The cDNA samples were amplified by real-time PCR with a
SYBR Premix ExTaq kit (TaKaRa) on an ABI PRISM 7900 HT cycler (Applied
Biosystems). The expression of target genes was normalized to expression
of housekeeping gene Rpl13a.
In Vivo Neutralizing with TGFb and IL23R Antibodies
The neutralizing mouse TGFb antibody 1D11.16.8 (BE0057) and isotype IgG
(BE0083) were purchased from Bio X cell. The neutralizing mouse IL-23 recep-
tor (IL-23R) antibody (MAB1686) and isotype IgG (MAB0061) were obtained
from R&D. For DSS-induced colitis, a total of 1 mg TGFb antibody or control500 Immunity 43, 488–501, September 15, 2015 ª2015 Elsevier Inc.isotype IgG and 250 mg of IL-23R antibody or control isotype IgGwere intraper-
itoneally injected intomice every other day starting at day 0 (days 0, 2, 4, 6, and
8). Mice were killed at day 10 for colon tissue analysis and LPL isolation.
Statistics
Data are presented as mean ± SEM. A two-tailed Student’s t test was used for
analysis of differences between the groups. p values of < 0.05were considered
statistically significant.
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